SeaSpine Holdings

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SeaSpine Holdings (NASDAQ:SPNE) reported its Q3 earnings results on Thursday, October 28, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

SeaSpine Holdings: Q3 Earnings Insights

Provides Financial Outlook for Fourth Quarter 2021 Provides Financial Outlook for Fourth Quarter 2021

SeaSpine Reports Third Quarter 2021 Financial Results

CARLSBAD, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Thursday, October 28, 2021. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

SeaSpine to Report Third Quarter 2021 Financial Results on October 28, 2021

CARLSBAD, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of its NorthStar OCT Posterior Cervical Fixation System. The launch of NorthStar OCT represents the Company's first full commercial introduction of a new posterior cervical system since 2007 and provides a differentiated and more robust product offering to address a market segment that SeaSpine estimates to exceed $250 million in the United States alone.

SeaSpine Announces Full Commercial Launch of The NorthStar OCT Posterior Cervical Fixation System

CARLSBAD, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the successful completion of the first cases in both the United States and Australia for the 7D Percutaneous Spine Module. The release of the Percutaneous Module represents a new application and increased functionality for its 7D Flash™ Navigation System that allows SeaSpine to address the minimally invasive spine surgery market, which SeaSpine estimates at approximately $4 billion worldwide.

SeaSpine Announces First Cases of 7D Surgical Percutaneous Spine Module for Minimally Invasive Surgery

Contract awarded for products that potentially bring improvement to health care industry Contract awarded for products that potentially bring improvement to health care industry

SeaSpine® Receives Innovative Technology Contract from Vizient for its 7D FLASH™ Navigation System

CARLSBAD, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced it received simultaneous CE Mark certification for its Cranial Module and Percutaneous Spine Module for the 7D FLASH™ Navigation System. This achievement expands the applications and functionality of the FLASH Navigation System for cranial surgery and minimally invasive spine surgery for the European market and additional global regions.

SeaSpine Announces CE Mark Certification of 7D Surgical Cranial Module and Percutaneous Spine Module for Minimally Invasive Spine Surgery

SeaSpine Holdings Corp (NASDAQ: SPNE) is the latest medical device maker warning that the SARS-CoV-2 Delta variant wave is hurting its business. The Company filed an update for investors with the SEC, citing “ongoing uncertainty regarding the duration and severity of COVID-19 and/or staffing shortages on spine surgery procedure volumes throughout the U.S.”

SeaSpine Warns Surgical Revenue To Be Hit By COVID-19

OrthoPediatrics

Orthofix International

Stryker

Zimmer Biomet Hlds

OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.

5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space

CARLSBAD, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021, beginning at 8:00 am ET.

SeaSpine to Participate in the Cantor Virtual Global Healthcare Conference

CARLSBAD, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will host an Analyst & Investor Event in Boston, Massachusetts on Thursday, September 30 from 7:30 a.m. to 8:45 a.m. Eastern Time.

SeaSpine to Host Analyst & Investor Event on September 30, 2021

CARLSBAD, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch and completion of initial surgeries of the Mariner Adult Deformity Pedicle Screw System.

SeaSpine Announces Initial Launch of Mariner Adult Deformity System

CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its 3D-printed WaveForm A (ALIF) Interbody System.

SeaSpine Announces Limited Commercial Launch of the WaveForm® A (ALIF) 3D-Printed Interbody System

Hubbell

Mackinac Financial

The S&P 500 saw its trailing 12-month real earnings per share increase by a compound annual growth rate of nearly 6% over the past five years. The index's share price ($4,447.70 as of Wednesday) has grown by approximately 103.5% over the past five years.

3 Stocks Growing Earnings Fast

CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has issued inducement awards to nine non-executive employees.

SeaSpine Reports Granting of Inducement Awards

SeaSpine Holdings Corporation (NASDAQ: SPNE) posted a narrower than expected second-quarter EPS loss of $(0.16), beating the consensus forecast of $(0.32) and lower than $(0.50) posted a year ago. Sales of $47.5 million, ahead of the consensus of $45.9 million, increased 66% Y/Y and were up 21% compared to the second quarter of 2019.

SeaSpine Beats Street In Q2 On Higher Sales From Spinal Implants, Orthobiologics; Raises FY2021 Sales Outlook

SeaSpine Holdings Corp. (SPNE) CEO Keith Valentine on Q2 2021 Results - Earnings Call Transcript

Shares of SeaSpine Holdings (NASDAQ:SPNE) moved higher in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 68.00% over the past year to ($0.16), which beat the estimate of ($0.32).

SeaSpine Holdings: Q2 Earnings Insights

SeaSpine Reports Second Quarter 2021 Financial Results

CARLSBAD, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021, beginning at 2:00 PM ET.

SeaSpine to Participate in the Canaccord Genuity 41st Annual Growth Conference

SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will SeaSpine Holdings (SPNE) Report Negative Q2 Earnings? What You Should Know

CARLSBAD, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Monday, August 2, 2021. Members of the Company's management team will host a corresponding conference call and webcast beginning at 2:00 pm PT / 5:00 pm ET.

SeaSpine to Report Second Quarter 2021 Financial Results on August 2, 2021

The FDA has given 510(k) clearance to SeaSpine Holdings Corporation's (NASDAQ:SPNE) 7D Percutaneous Spine Module for minimally invasive surgery.  This news follows SeaSpine's recent acquisition of 7D Surgical, a Toronto-based company that develops advanced optical technologies and machine vision-based registration algorithms for surgical navigation to improve patient care.

SeaSpine Stock Is Trading Higher On FDA Approval For 7D Surgical Spine Module

CARLSBAD, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the FDA 510(k) clearance of its 7D Percutaneous Spine Module for minimally invasive surgery. This represents a new application and increased functionality for its 7D Flash™ Navigation System. This news follows SeaSpine's recent acquisition of 7D Surgical, a Toronto-based company that develops advanced optical technologies and machine vision-based registration algorithms for surgical navigation to improve patient care. The Company is preparing a limited release of the Percutaneous Spine Module in the third quarter.

SeaSpine Announces FDA 510(k) Clearance of 7D Surgical Percutaneous Spine Module for Minimally Invasive Surgery

CARLSBAD, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021, beginning at 10:30 AM ET.

News for SeaSpine Holdings Stock (SPNE)